$39.93 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
Equities research analysts expect that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post $39.93 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest sales estimate coming in at $32.75 million and the highest estimate coming in at $47.10 million. Sangamo Therapeutics reported sales of $11.81 million in the same quarter last year, which indicates a positive year-over-year growth rate of 238.1%. The business is scheduled to announce its next earnings report on Thursday, November 8th.
On average, analysts expect that Sangamo Therapeutics will report full-year sales of $94.08 million for the current financial year, with estimates ranging from $50.00 million to $118.33 million. For the next financial year, analysts anticipate that the company will post sales of $98.89 million per share, with estimates ranging from $50.00 million to $129.17 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm had revenue of $21.42 million for the quarter, compared to the consensus estimate of $21.43 million. During the same period in the prior year, the business earned ($0.17) earnings per share. The company’s revenue for the quarter was up 159.6% on a year-over-year basis.
Sangamo Therapeutics traded up $0.35, hitting $15.65, during trading on Tuesday, Marketbeat reports. 2,113,880 shares of the stock traded hands, compared to its average volume of 1,967,697. Sangamo Therapeutics has a one year low of $9.50 and a one year high of $27.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 4.78.
In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $13.45, for a total transaction of $67,250.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 30,000 shares of company stock worth $458,700 over the last ninety days. 1.20% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of SGMO. NumerixS Investment Technologies Inc acquired a new position in Sangamo Therapeutics during the second quarter valued at approximately $125,000. Riverhead Capital Management LLC boosted its holdings in shares of Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,667 shares during the period. Tyers Asset Management LLC boosted its holdings in shares of Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 7,232 shares during the period. Meadow Creek Investment Management LLC boosted its holdings in shares of Sangamo Therapeutics by 301.3% in the second quarter. Meadow Creek Investment Management LLC now owns 16,856 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 12,656 shares during the period. Finally, Tiverton Asset Management LLC acquired a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $242,000. Institutional investors own 57.49% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Featured Story: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.